Developer of gene therapy designed to treat cancer patients. The company's gene therapy uses nano-technology, commercializes human cancer medicines and tumor apoptosis enhancer drugs to optimize chemotherapy, enabling patients to receive effective oncology therapies at an affordable cost.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Out of Business | 01-Aug-2018 | 00.000 | Completed | Out of Business | ||
2. Early Stage VC | 27-Jul-2017 | 00.000 | 00.000 | 00.000 | Completed | Startup |
1. Early Stage VC | 07-Jan-2016 | $2.19M | $2.19M | 00.000 | Completed | Startup |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary 1 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 | |
Ordinary | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000000 | 19-Jul-2018 | 000000000000000000 | 00.000 | Other Healthcare Technology Systems | 0000 000000 |